Seguir
Eileen Parkes
Eileen Parkes
Academic Clinical Lecturer Queen's University Belfast
Dirección de correo verificada de qub.ac.uk
Título
Citado por
Citado por
Año
Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer
EE Parkes, SM Walker, LE Taggart, N McCabe, LA Knight, R Wilkinson, ...
Journal of the National Cancer Institute 109 (1), djw199, 2017
4072017
Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application
G Lightbody, V Haberland, F Browne, L Taggart, H Zheng, E Parkes, ...
Briefings in bioinformatics 20 (5), 1795-1811, 2019
1672019
Metastasis and immune evasion from extracellular cGAMP hydrolysis
J Li, MA Duran, N Dhanota, WK Chatila, SE Bettigole, J Kwon, RK Sriram, ...
Cancer discovery 11 (5), 1212-1227, 2021
1632021
Development of immunotherapy combination strategies in cancer
TA Yap, EE Parkes, W Peng, JT Moyers, MA Curran, HA Tawbi
Cancer discovery 11 (6), 1368-1397, 2021
1622021
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model
Y Philippou, HT Sjoberg, E Murphy, S Alyacoubi, KI Jones, ...
British journal of cancer 123 (7), 1089-1100, 2020
602020
The tumor microenvironment and immune responses in prostate cancer patients
JTW Kwon, RJ Bryant, EE Parkes
Endocrine-Related Cancer 28 (8), T95-T107, 2021
522021
Automated tumour recognition and digital pathology scoring unravels new role for PD-L1 in predicting good outcome in ER-/HER2+ breast cancer
MP Humphries, S Hynes, V Bingham, D Cougot, J James, F Patel-Socha, ...
Journal of Oncology 2018, 2018
522018
Non-cell-autonomous cancer progression from chromosomal instability
J Li, MJ Hubisz, EM Earlie, MA Duran, C Hong, AA Varela, E Lettera, ...
Nature 620 (7976), 1080-1088, 2023
382023
Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c trial
P Sharma, WE Barlow, AK Godwin, EE Parkes, LA Knight, SM Walker, ...
Journal of Clinical Oncology 37 (36), 3484, 2019
382019
A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer
NE Buckley, P Haddock, RDM Simoes, E Parkes, G Irwin, F Emmert-Streib, ...
Oncotarget 7 (15), 19884, 2016
342016
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers
MATM van Vugt, EE Parkes
Trends in cancer 8 (3), 174-189, 2022
292022
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
RC Turkington, LA Knight, JK Blayney, M Secrier, R Douglas, EE Parkes, ...
Gut 68 (11), 1918-1927, 2019
252019
DNA repair deficiency in breast cancer: opportunities for immunotherapy
E Gilmore, N McCabe, RD Kennedy, EE Parkes
Journal of oncology 2019, 2019
252019
Scientific progress is built on failure
E Parkes
Nature 10, 2019
242019
The clinical and molecular significance associated with STING signaling in breast cancer
EE Parkes, MP Humphries, E Gilmore, FA Sidi, V Bingham, SM Phyu, ...
NPJ Breast Cancer 7 (1), 81, 2021
222021
Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study
RS McCain, DT McManus, S McQuaid, JA James, M Salto-Tellez, ...
Cancer causes & control 31, 1-11, 2020
222020
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer
EE Parkes, KI Savage, T Lioe, C Boyd, S Halliday, SM Walker, K Lowry, ...
British journal of cancer 126 (2), 247-258, 2022
202022
cGAS–STING signalling in cancer: striking a balance with chromosomal instability
B Beernaert, EE Parkes
Biochemical Society Transactions 51 (2), 539, 2023
132023
Development of immunotherapy combination strategies in cancer. Cancer Discov. 2021; 11: 1368–1397. doi: 10.1158/2159-8290
TA Yap, EE Parkes, W Peng, JT Moyers, MA Curran, HA Tawbi
CD-20-1209.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
12
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer
CE Fletcher, L Deng, F Orafidiya, W Yuan, M Lorentzen, OW Cyran, ...
Molecular Cancer 21 (1), 82, 2022
102022
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20